Cargando…
An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma
The aim of this study was to assess the prognostic value of pretreatment clinical and laboratory parameters in refractory or relapsed multiple myeloma (MM) patients who have a long-term response to thalidomide (THAL), lasting at least 18 months. The study was carried out on 234 patients who received...
Autores principales: | Hus, I, Dmoszynska, A, Manko, J, Hus, M, Jawniak, D, Soroka-Wojtaszko, M, Hellmann, A, Ciepluch, H, Skotnicki, A, Wolska-Smolen, T, Sulek, K, Robak, T, Konopka, L, Kloczko, J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409770/ https://www.ncbi.nlm.nih.gov/pubmed/15520820 http://dx.doi.org/10.1038/sj.bjc.6602225 |
Ejemplares similares
-
Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma
por: Hus, Marek, et al.
Publicado: (2011) -
The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma
por: Giannopoulos, K, et al.
Publicado: (2012) -
New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014) -
Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma
por: Robak, Marta, et al.
Publicado: (2012) -
Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2020)